You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

 

1545 Results
Regimen
Cancer Type:
Gynecologic, 
Vulva
Intent: Adjuvant, Palliative
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Anus
Intent: Adjuvant
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct, 
Pancreas
Intent: Palliative
Apr 2023
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
Aug 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
Aug 2020
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Apr 2023
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Apr 2023
Regimen
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Apr 2023
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Palliative
Funding:
Exceptional Access Program
    lenvatinib - In Combination with Pembrolizumab for Advanced Endometrial Cancer
New Drug Funding Program
    Pembrolizumab - In Combination with Lenvatinib for Advanced Endometrial Cancer
Aug 2023

Pages